ArticleCureus2025
Molecular Characterization of Carbapenem and Colistin Resistance in Isolates Causing Urinary Tract Infections at an Outpatient Setting of a Tertiary Care Hospital.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Increasing resistance to higher-end antibiotics like carbapenems and colistin is a great cause of concern. There is a paucity of data on the detection of carbapenem and colistin in outpatient settings. This study was to determine the prevalence of carbapenem-resistant Enterobacterales (CRE) and colistin resistance in CRE at the outpatient setting of a tertiary care institute of North India. Methods A prospective study was conducted from January to December 2020. A total of 6,829 non-repetitive urine samples were cultured on cysteine lactose electrolyte-deficient (CLED) agar. Identification was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), and antimicrobial susceptibility testing followed Clinical and Laboratory Standards Institute (CLSI) 2020, using Kirby-Bauer and Vitek 2 (BioMérieux, Marcy-l'Étoile, France). Carbapenem-resistant isolates were screened for carbapenemase genes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.